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Objectives: Heparin coating of the cardiopulmonary bypass circuit is shown to
improve the biocompatibility of the surface. We have studied a new heparin surface,
the Corline Heparin Surface, applied to a complete set of an extracorporeal device
used during coronary artery bypass grafting in terms of activation of inflammation,
coagulation, and fibrinolysis in patients and in shed mediastinal blood.
Methods: Sixty patients scheduled for coronary artery bypass grafting were ran-
domized to one of 3 groups with heparin-coated devices receiving either a standard,
high, or low dose of systemic heparin or to an uncoated but otherwise identical
circuit receiving a standard dose of systemic heparin. Samples were drawn before,
during, and after the operation from the pericardial cavity and in shed mediastinal
blood. No autotransfusion of shed mediastinal blood was performed.
Results: The Corline Heparin Surface significantly reduced the activation of coag-
ulation, fibrinolysis, platelets, and inflammation compared with that seen with the
uncoated surface in combination with a standard dose of systemic heparin during
cardiac surgery with cardiopulmonary bypass. Both a decrease and an increase of
systemic heparin in combination with the coated heparin surface resulted in higher
activation of these processes. A significantly higher expression of all studied
parameters was found in the shed mediastinal blood compared with in systemic
blood at the same time.
Conclusions: The Corline Heparin Surface used in cardiopulmonary bypass proved
to be more biocompatible than an uncoated surface when using a standard systemic
heparin dose. The low dose of systemic heparin might not be sufficient to maintain
the antithrombotic activity, and the high dose resulted in direct cell activation rather
than a further anti-inflammatory and anticoagulatory effect.
During cardiac surgery with cardiopulmonary bypass (CPB), thebody is subject to extensive trauma, and the blood is exposed toa large artificial surface, leading to activation of inflammation andcoagulation. Many factors during CPB can induce complex in-flammatory response involving complement and cellular activa-tion, along with the production of cytokines. It has been suggested
that the systemic inflammatory response in patients undergoing coronary artery
bypass grafting (CABG) is caused mainly by the surgical procedure.1 Thrombin
generation during cardiac surgery with CPB might be caused by the surface of the
extracorporeal unit, with the oxygenator, pump, and connections between the patient
and the extracorporeal device.2 The surgical trauma with exposure of tissue factor
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(TF), the principal initiator of blood coagulation, is also
suggested to be of major importance for thrombin genera-
tion.3-5 Previously, it was thought that the activation of
coagulation during CPB occurred mainly through contact
activation. However, current evidence suggests that activa-
tion of the TF-induced pathway might be the most important
mechanism of thrombin generation during this type of op-
eration.6-8 Heparinization is required to prevent clotting in
the extracorporeal circuit during cardiac surgery, and hep-
arin coating has been reported to improve the biocompat-
ibility of artificial surfaces in contact with circulating
blood.9 Moreover, the enhanced biocompatibility of CPB
circuits by means of heparin coating has led to the idea of
reducing the systemic heparinization during cardiac sur-
gery. This was shown to be clinically safe, with a lower
incidence of homologous transfusion and thromboembolic
complications, although no differences in markers for in-
flammation, coagulation, and fibrinolysis.10-12
Retransfusion of shed mediastinal blood (SMB) was
introduced by Schaff and colleagues13 in 1978 and has
become a widely used method during and after cardiac
surgery.14,15 However, a number of studies have shown that
the composition of the shed blood is far from normal.16,17
SMB after CABG is characterized by extraordinary acti-
vated coagulation and fibrinolysis.18-20 Furthermore, high
levels of proinflammatory cytokines are found in shed
blood.20 However, the interpretations of the outcome of
retransfusion of this blood differs; some studies have con-
cluded that retransfusion of shed blood deteriorates hemo-
stasis, fibrinolysis, and inflammation, whereas others sug-
gest that it does not.16,17,20-22
A new heparin surface, the Corline Heparin Surface
(CHS), has been prepared by the use of a macromolecular
conjugate of covalently bonded heparin. In this study we
have, for the first time, investigated the effects in CPB of the
CHS in combination with different concentrations of sys-
temic heparin on leukocytes, platelets, coagulation, and
inflammatory responses compared with effects achieved
with an uncoated device. The aim was to further study the
combination of cell and tissue activation, inflammation, and
coagulation in both systemic and shed blood during and
after cardiac surgery with CPB.
Material and Methods
Patients
This randomized study comprised 60 patients younger than 75
years of age scheduled for elective CABG. Patients with inflam-
matory or renal disease or severely low ejection fraction were not
considered for the study. Informed consent was obtained from all
patients, and the study was approved by the Swedish Medical
Product Agency and the ethical committee of the Medical Faculty
at Uppsala University.
The study was planned and performed in 2 parts, with a short
delay between the 2 parts giving time for analyses of some im-
portant parameters to survey the in vivo effects of the new surface.
In the first part patients were randomly assigned to group 1 (n 
15) for the use of an uncoated circuit (Jostra Medizintechnic AG,
Hirrlingen, Germany) and to group 2 (n  15) for a completely
heparin-coated (Corline Heparin Surface; Corline Systems AB,
Uppsala, Sweden) but otherwise identical device. Both groups
received a standard dose of systemic heparin, corresponding to an
activated clotting time (ACT) of 480 seconds. In the second part of
the study, the CHS was used in all patients (groups 3 and 4). In
group 3 (n  15) patients were randomized to a low dose of
systemic heparin (ACT of 300 seconds) and group 4 (n  15) to
a high dose of systemic heparin (ACT of 600 seconds).
No autotransfusion of SMB was performed during this study.
Heparin Surface
The CHS was applied to a complete set of an extracorporeal circuit
(tubing, cannula, oxygenator, and reservoir). The CHS uses a
unique macromolecular conjugate in which approximately 70 hep-
arin molecules are covalently linked to a polymer carrier having a
molecular weight of 50 kd. The specificity of the covalent linkages
ensures that the antithrombin III-binding pentasaccharide sequence
of heparin are left intact. The CHS coating comprises a condition-
ing layer of a polymeric cationic amine onto which the macromo-
lecular conjugate is irreversibly attached by means of multiple
ionic interactions. The surface concentration of heparin is 0.5 to 1
g/cm2, and the capacity to bind antithrombin is 2 to 4 pmol/cm2.23
An extracorporeal closed-loop system modified with CHS used
during extracorporeal circulation for 24 hours in pigs without any
systemic dose of heparin had no effect on the clotting time (data
submitted to the Swedish Medical Products Agency).
Anesthesia and Analgesia
Patients were premedicated with morphine or morphine-scopol-
amine on the morning of the operation. Anesthesia followed con-
ventional procedures with thiopental sodium used for induction
and a combination of pancuronium bromide and inhaled isoflurane
used during the operation. After weaning from CPB, propofol in
continuous infusion was used as an anesthetic agent. Alfentanil
hydrochloride and fentanyl citrate were used for intraoperative
analgesia.
Cardiopulmonary Bypass
Techniques and equipment for CPB were similar in all patients.
The standard set consisted of a Sto¨ckert roller pump (Sto¨ckert
Instrumente GMBH, Munich, Germany) with a Quadrox hollow-
fiber oxygenator (Jostra) and a hard-shell venous reservoir (Jostra).
The tubing, including cannula, was CHS coated from tip to tip (9
patients had uncoated cannulas because of surgeons’ preferences).
The circuit was primed with 1500 to 2000 mL of asanguineous
fluid containing 5000 IU of heparin. The operation was performed
with moderate hypothermia (32°C-35°C), and the patients were
rewarmed to a rectal temperature of 36°C before weaning from
CPB. The flow was nonpulsatile, initially 2.4 L  m-2  min-1, and
gradually reduced to 2.0 L  m-2  min-1 during hypothermia.
Anticoagulation and Operative Procedures
Patients in groups 1 and 2 were anticoagulated by means of
intravenous administration of heparin administered as a bolus of
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300 IU/kg body weight after completed dissection of the internal
thoracic artery and before cannulation for CPB. In groups 3 and 4
the bolus doses of heparin were 200 and 400 IU/kg body weight,
respectively. If necessary, additional doses of heparin were given
to maintain the desired ACT. After decannulation, heparin was
reversed with protamine chloride in a 1:1 proportion to the admin-
istrated heparin dose. ACT was measured repeatedly throughout
the operation with an ACT II (Medtronic Inc, Minneapolis, Minn)
to assess adequate anticoagulation. Cardioplegic arrest was
achieved with antegrade infusion of modified St Thomas’ car-
dioplegic solution at 4°C through the aortic root. During the CPB
procedure, cardiotomy suction was used. Blood remaining in the
CPB circuit after decannulation was collected in an infusion bag
and immediately retransfused. Postoperatively, shed blood was
collected in the reservoir, but no retransfusion was performed.
Blood Sampling and Laboratory Procedures
Blood samples were drawn from a catheter in the radial artery after
induction of anesthesia, at sternotomy, at the start and end of CPB,
30 minutes after protamine administration, and 3, 8, and 20 hours
after CPB. Sampling was also performed from the pericardial
cavity at the end of CPB and from the drainage reservoir (after
gentle mixing of the reservoir) 3 hours after CPB. Vacutainer tubes
containing Na-citrate or ethylenediamine tetraacetic acid K3 (Bec-
ton Dickinson, Meylan Cedex, France) were used. One citrated
sample was immediately brought to the laboratory for cell count
and analysis of cellular surface antigens by means of flow cytom-
etry. The other samples were immediately centrifuged at 2000g for
20 minutes, and plasma was frozen and stored in aliquots at70°C
until analysis.
Platelet and leukocyte differential counts were determined with
an automatic cell counter (Coulter STKS; Coulter Electronics,
Hialeah, Fla). Plasma levels of prothrombin fragment 12 (F12),
thrombin-antithrombin (TAT), plasmin/2-antiplasmin complex
(PAP), human myeloperoxidase (MPO), and the cytokines inter-
leukin (IL) 6, IL-8, IL-10, and soluble IL-2 receptor (sIL-2R) were
quantified by means of sandwich enzyme-linked immunosor-
bent assay techniques (Enzygnost for F12, TAT, and PAP from
Behringswerke, Marburg, Germany; Bioxytech for MPO enzyme
immunoassay from Oxis International, Inc Portland, Ore; and
Quantikine for IL-6, IL-8, IL-10 and sIL-2R from R&D Systems,
Abingdon, United Kingdom). In a reference group of 71 healthy
individuals, reference intervals (2.5th-97.5th percentile) for F12
and TAT were 0.4 to 1.5 nmol/L and 1.2 to 5.0 g/L, respectively,
with respective medians of 0.8 nmol/L and 2.3 g/L. For both
assays, the intra-assay and interassay variations were 5% and 9%.
In a reference group of 466 healthy individuals, reference intervals
(2.5th-97.5th percentile) for PAP was 120 to 700 g/L, with a
median of 290 g/L. The intra-assay and interassay variations
were 4% and 7%, respectively. Plasma soluble fibrin (sF) was
analyzed with an assay using a chromogenic, plasmin-specific
substrate (Bericrom FM, Behring Diagnostics GmbH). In 73
healthy individuals aged 21 to 66 years (median, 28 years), the
reference interval (2.5th-97.5th percentile) for sF was 17 mg/L or
less (median, 9.0 mg/L; range, 3.2-16.6 mg/L), and the intra-assay
and interassay variations had a total coefficient of variation of
7.9%. Reference intervals for the cytokines were according to the
manufacturer:
● For IL-6, in a reference group of 40 healthy individuals, 33
had measurements of less than 3.13 pg/mL, and 7 had mea-
surements of between 3.13 and 12.5 pg/mL.
● For IL-8, a reference group of 34 healthy individuals had
measurements of less than 31.2 pg/mL.
● For IL-10, a reference group of 40 healthy individuals had
measurements of less than 7.8 pg/mL.
● For sIL-2R, a reference group of 37 healthy individuals had
measurements of 1057 pg/mL (404-2604 pg/mL).
The intra- and interassay variations were 1.7% and 3.3% for
IL-6, 5.4% and 9.7% for IL-8, 4.3% and 7.5% for IL-10, and 6.1%
and 6.0% for sIL-2R, respectively.
Determination of activated coagulation factor XI-antithrombin
complex (FXIa-AT), activated coagulation factor XII-antithrombin
complex (FXIIa-AT), and activated coagulation factor XII-C1-
esterase inhibitor complex (FXIIa-C1 INH) were performed by
using a solid-phase enzyme-linked immunosorbent assay accord-
ing to the method of Sanchez and colleagues.24 The intra-assay
coefficient of variation was less than 4% in all assays. Cross-
reactions between antibodies to FXIa and FXIIa or antibodies
against AT and C1 INH were less than 5%.
No correction for hemodilution was made.
Flow Cytometry
Leukocytes. Surface antigen expression was analyzed by using
a Coulter Epics XL-MCL flow cytometer (Beckman Coulter, Ful-
lerton, Calif). Whole blood was labeled with a murine monoclonal
flourescein isothiocyanate (FITC)-conjugated anti-TF antibody
(TF4508-CJ; American Diagnostica, Greenwich, Conn) or an anti-
CD11b antibody (Dakopatts A/S, Glostrup, Denmark). A murine
FITC-conjugated irrelevant antibody of the same subtype was used
as a negative control. The samples were incubated on ice for 30
minutes and lysed with Lyse (Beckman Coulter), washed, and
suspended in PBS. Flow cytometric analysis was then performed.
Gating of the cells was carried out with forward- and side-scatter
parameters, and the percentage of positive cells and mean fluores-
cence intensity were determined.
Platelets. Platelet-rich plasma was isolated by means of cen-
trifugation at 140g for 10 minutes at room temperature. Platelet-
rich plasma was added to tubes containing HEPES buffer and
FITC-labeled chicken polyclonal anti-P-selectin antibody (Immun-
system AB, Uppsala, Sweden) or FITC-labeled chicken polyclonal
anti-whole-platelet antibody (Biopool AB, Umeå, Sweden). The
samples were incubated in duplicate for 10 minutes at room
temperature and were then diluted and fixed with ice-cold PBS
containing 1% paraformaldehyde. No washing steps were used.
For P-selectin analysis, gating of the cells in the flow cytometer
was carried out by using forward- and side-scatter parameters, and
for microparticle analysis, gating was performed by using forward
scatter and fluorescence 1 (anti-whole-platelet antibodyFITC).
Platelets with fluorescence of less than a preset cut-off level were
identified as microparticles. The percentage of positive cells was
determined.
Statistical Analysis
Statistica for Windows (StatSoft, Tulsa, Okla) was used for all
statistical analyses. The results are presented as medians and
25th-75th percentile ranges. The Friedman analysis of variance test
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was used for analysis of time series within each group. When
significant differences were obtained, these were further evaluated
by using the Wilcoxon matched pairs test for comparison between
2 samples within the series. The Kruskal-Wallis analysis of vari-
ance test was used for an overall comparison between the groups.
When significant differences were obtained, these were further
evaluated with the Mann-Whitney U test for intergroup compari-
son. No adjustment for multiple testing was done. Hence this study
should be interpreted more as an exploratory, rather than a con-
firmative, study.
Results
The postoperative course and mobilization was uneventful
in all but one patient, included in group 1, who died the day
after the operation as a result of myocardial failure. This
patient was excluded from the study and left 49 men and 10
women for statistical calculations. Three patients received
Cyklokapron (tranexamic acid; Pharmacia & Upjohn
Sverige AB, Stockholm, Sweden) and Octostim (desmo-
pressinacetate; Ferring La¨kemedel AB, Limhamn, Sweden)
perioperatively. The 9 patients with uncoated aortacannulas
and the patients receiving tranexamic acid and desmopressi-
nacetate did not differ significantly in any clinical or labo-
ratory parameters and were equally spread between the
groups. Because there were no differences among the 4
groups in any parameters in the SMB, these results are
presented as one set. There were no significant differences
concerning age, CPB time, crossclamp time, or bleeding
among the 4 groups (Table 1).
Leukocyte Activation
The number of leukocytes increased from 5.6  109/L
(4.6-6.4  109/L) before the operation to 7.6  109/L
(6.2-10.2  109/L) at the end of CPB (P  .001). Three
hours after the operation, the number of leukocytes reached
maximum levels, 13.3  109/L (11.1-15.5  109/L). Sev-
enty-two hours after the operation, the levels were still
elevated compared with presurgical levels (11.0  109/L
[9.4-13.1  109/L], P  .001), although they were declin-
ing. The expression of CD11b on both monocytes and
granulocytes increased during the operation (P  .03 and
P  .001, respectively). At the end of the operation, the
expression of CD11b on both monocytes and granulocytes
was higher in group 3 (with reduced systemic heparin)
compared with that in group 2 (with standard systemic
heparin, P .008 for both cell types). The morning after the
operation, the CD11b expression on monocytes had de-
creased in both groups 2 and 3 (P  .04 and P  .02,
respectively). The expression of CD11b on granulocytes
decreased in all groups 3 hours after the operation (P 
.001) and further the morning after the operation (P .001),
in group 2 to presurgical levels (Figure 1).
The release of MPO was severely increased during the
TABLE 1. Clinical characteristics and intraoperative and postoperative data of the patient groups
Uncoated, ACT 480 s
(group 1)
CHS coated, ACT 480 s
(group 2)
CHS coated, ACT 300 s
(group 3)
CHS coated, ACT 600 s
(group 4)
Sex (no. of patients)
Male 10 13 14 12
Female 4 2 1 3
Age (y) 60 (54-67) 62 (55-70) 60 (53-69) 62 (55-70)
CPB time (min) 86 (72-100) 89 (75-110) 91 (72-107) 92 (72-110)
Aortic crossclamping
(min)
48 (36-58) 50 (44-66) 49 (37-62) 57 (34-62)
Surgical bleeding
(mL)
700 (550-772) 575 (400-650) 600 (400-775) 550 (400-850)
Postoperative
bleeding (mL)
900 (820-1025) 825 (640-1060) 925 (600-1200) 750 (650-1250)
Uncoated cannula
(No. of patients)
2 3 2 2
Allogenic blood
No. of patients 5 3 4 6
No. of units 11 7 8 14
ACT at start of CPB
(s)
512*† (433-579) 536*† (497-568) 400† (352-463) 642* (557-685)
ACT at end of CPB
(s)
475*† (417-521) 463*† (426-506) 343† (303-406) 568* (479-685)
Heparin (IU/mL) 31,250*† (30,000-35,000) 35,000*† (30,000-40,000) 25,000† (20,000-25,000) 40,000* (37,500-45,000)
Protamine (U/mL) 350*† (350-362) 400*†(350-450) 300† (250-300) 450* (425-475)
No significant differences existed between the groups for the clinical parameters. Data are presented as median and 25th-75th percentiles.
*Significantly different from group 3, P  .001.
†Significantly different from group 4, P  .001.
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operation (P  .001) and was not completely normalized
the day after the operation, although they were lower (P 
.001) in all groups. In group 2 there were lower levels
compared with those in the uncoated group, group 1, at the
end of CPB (P  .05) and also 3 hours after the operation
(P  .04). A reduction of the systemic heparin dose in
combination with the heparin-coated surface resulted in
lower levels of MPO 30 minutes after the operation com-
pared with the standard heparin dose (P  .03, Figure 2).
The expression of TF on the surface of monocytes was
upregulated 3 hours after the operation (P  .003) and
remained increased the morning after the operation (P 
.001, Table 2).
Leukocyte Activation in the Pericardial Cavity
The surface expression of CD11b on granulocytes and
monocytes from the pericardial cavity was more than 3 and
4 times higher, respectively, than on cells from the circu-
lating blood at the end of CPB (P  .001 for both cell
types). Monocytes from the pericardial cavity expressed
almost 2 times more TF than the circulating cells at the
same time (P .001). There were no statistically significant
differences between the groups (Table 2).
Platelet Activation
The number of platelets in circulating blood was decreased
during the operation in all groups, from 160  109/L (134-
Figure 1. CD11b expression on granulocytes before, during, and
after the operation in patients. A, Uncoated group with ACT of 480
seconds (open squares) and CHS-coated group with ACT of 480
seconds (filled squares) ; B, CHS-coated group with low heparin
dose and ACT of 300 seconds (open triangles), with high heparin
dose and ACT of 600 seconds (filled triangles), and with standard
heparin dose and ACT of 480 seconds (filled squares, dotted line).
##P  .008, ACT of 300 seconds versus ACT of 480 seconds.
Results are presented as median and 25th-75th percentile. MFI,
Mean fluorescence intensity.
Figure 2. MPO in plasma before, during, and after the operation in
patients. A, Uncoated group with ACT of 480 seconds (open
squares) and CHS-coated group with ACT of 480 seconds (filled
squares) *P  .05, **P .04. B, CHS-coated group with low
heparin dose and ACT of 300 seconds (open triangles) and with
high heparin dose and ACT of 600 seconds (filled triangles) *P 
.01, **P  .002. Results are presented as median and 25th-75th
percentiles.
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182  109/L) to 107  109/L (77-136  109/L, P  .001).
In the uncoated group, group 1, and the heparin-coated
group with high systemic heparin, group 4, the decrease was
even more pronounced in comparison with that in the hep-
arin-coated group with standard heparin dose, group 2 (P 
.03 and P  .02, respectively), probably because of the
activation and adhesion in these groups. Forty-eight hours
after the operation, the platelets had returned to presurgical
levels in all groups. The expression of P-selectin on circu-
lating platelets was increased during the operation in all
groups (P  .001); however, this expression was less in
group 2 than in group 1 (P  .004). This positive effect of
the heparin surface was not affected by the systemic heparin
dose (Figure 3). The formation of platelet microparticles in
the circulating blood was not significantly altered in any
group during the operation (data not shown).
Release of Cytokines
The proinflammatory cytokines IL-6 and IL-8 were in-
creased during the operation (P .001) in all groups. There
were no statistically significant differences between the
groups. IL-6 continually increased until 3 hours after the
operation, whereas IL-8 reached the maximum level at 30
minutes after protamine administration. The day after the
operation, both IL-6 and IL-8 were still increased (P .001
for both). The release of the anti-inflammatory cytokine
IL-10 was 8-fold increased in all groups during the opera-
tion (P  .001). Three hours after the operation, the levels
were lower (P  .001), although increased, and remained
increased the following morning. sIL-2R decreased during
the operation (P .001), with minimum levels at the end of
CPB. The morning after the operation, sIL-2R was elevated
compared with levels before the operation (P  .001). All
fluctuations were within the normal range for sIL-2R. There
were no statistical differences among the groups (Table 3).
Activation of the Coagulation Cascade
Thrombin generation measured as F12 and TAT (TAT data
not shown, consistent with F12) increased early during the
operation in all groups (P  .001). A further increase of
F12 was recorded during (P  .001) and 30 minutes after
(P  .001) CPB, although levels were lower in group 2
compared with those in all other groups (P  .01). Eight
and 20 hours after the operation, the generation of thrombin
was lower in all groups compared with levels at the end of
the operation (P  .001), although not reaching presurgical
levels (Figure 4). The levels of sF, reflecting thrombin
activity, were increased in all groups during the operation,
from 17 mg/L (14-22 mg/L) before the operation to 28 mg/L
(22-33 mg/L) at the end of CPB (P  .001), with remaining
high levels the morning after the operation.
Fibrinolysis
PAP was increased during CPB (P  .001), with a further
increase in all groups until 3 hours after the operation (P 
.001), although it was less in group 2 (P .01). Eight hours
TABLE 3. Cytokines in plasma before, during, and after the operation in patients and SMB
Cytokine
Before
operation
(n  59)
Sternotomy
(n  59)
Start of CPB
(n  59)
End of CPB
(n  59)
30 min after
CPB (n  59)
3 h after
operation
(n  59)
8 h after
operation
(n  57)
20 h after
operation
(n  59)
IL-6 2 (1-4) 3† (2-4) 3‡ (2-6) 22‡ (11-40) 68‡ (44-104) 160‡ (112-220) 130‡ (104-192) 97‡ (63-147)
IL-8 4 (4-6) 5‡ (4-8) 6‡ (4-9) 15‡ (7-31) 33‡ (19-52) 28‡ (18-42) 20‡ (15-27) 12‡ (9-17)
IL-10 8 (6-12) 9 (6-15) 9* (7-17) 65‡ (34-119) 72‡ (43-120) 24‡ (17-42) 27‡ (18-40) 19‡ (14-26)
sIL-2R 760 (600-940) 710† (580-920) 710 (620-930) 560‡ (440-680) 670‡ (550-840) 760‡ (620-1010) 890‡ (750-1180) 1250‡ (1000-1620)
No statistically significant differences existed between the groups. Results are presented as one set. Data are presented in picograms per milliliter and
as median and 25th-75th percentiles.
*Significantly different from before the operation, P  .01.
†Significantly different from before the operation, P  .001.
‡Significantly different from before the operation, P  .001.
TABLE 2. TF expression on monocytes before, during, and after the operation
Before operation
(n  59)
Start of CPB
(n  58)
End of CPB
(n  58)
Pericardial
cavity (n  58)
3 h after operation
(n  59)
20 h after operation
(n  58)
TF (MFI) 0.50 (0.44-0.54) 0.51 (0.47-0.56) 0.49 (0.46-0.53) 0.84* (0.72-1.0) 0.52† (0.48-0.58) 0.54‡ (0.49-0.58)
No statistically significant differences existed between the groups. Results are presented as one set and as median and 25th-75th percentiles. MFI, Mean
fluorescence intensity.
*Significantly different from end of CPB, P  .001.
†Significantly different from before the operation, P  .003.
‡Significantly different from before the operation, P  .001.
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after the operation, the levels of PAP were lower (P .001)
and even normalized in group 2. The next morning, PAP
levels were normalized in all groups (Figure 5).
Intrinsic Pathway
The formations of FXIa-AT and FXIIa-AT increased during
the operation and returned to presurgical levels the follow-
ing morning. FXIa-AT reached maximum level at the end of
CPB in all groups (P  .001); however, this was lower in
group 2 compared with that in group 4 (P  .05, data not
shown). The increase of FXIIa-AT was, however, earlier,
starting before CPB. Groups 1 and 2 reached maximum
levels at the start of CPB, whereas group 3 and 4 levels
increased further during CPB (P  .001, Figure 6). The
formation of FXIIa-C1 INH increased during CPB, al-
though significantly only in group 3 (P  .003). There was
a decrease after CPB in all groups (P  .001) except group
1 (P  .8), followed by an increase in all groups until 20
hours after the operation (P  .001, data not shown).
Shed Mediastinal Blood
In the SMB the number of leukocytes was 4-fold lower
(P  .001) in all groups compared with circulating blood 3
hours after the operation. Both granulocytes and monocytes
showed 5 times higher expression of CD11b compared with
the circulating cells (P  .001 for both). The release of
Figure 3. P-selectin expression on platelets before, during, and
after the operation in patients. A, Uncoated group with ACT of 480
seconds (open squares) and CHS-coated group with ACT of 480
seconds (filled squares) *P  .005, **P  .004. B, CHS-coated
group with low heparin dose and ACT of 300 seconds (open
triangles) and with high heparin dose and ACT of 600 seconds
(filled triangle). Results are presented as median and 25th-75th
percentiles.
Figure 4. F12 in plasma before, during, and after the operation in
patients. A, Uncoated group with ACT of 480 seconds (open
squares) and CHS-coated group with ACT of 480 seconds (filled
squares). *P  .05, **P  .02, ***P  .008. B, CHS-coated group
with low heparin dose and ACT of 300 seconds (open triangles),
high heparin dose and ACT of 600 seconds (filled triangles), and
standard heparin dose and ACT of 480 seconds (filled squares,
dotted line. *P  .02, ACT of 300 seconds versus ACT of 600
seconds; #P .03, ACT of 300 seconds versus ACT of 480 seconds;
##P  .005; ###P < .001; ¤P  .004, ACT of 600 seconds versus
ACT of 480 seconds; ¤¤P  .008; ¤¤¤P < .001. Results are pre-
sented as median and 25th-75th percentiles.
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MPO was 15 times higher than in the circulating blood at
the same time (P  .001). Monocytes in the SMB showed
almost 2-fold higher expression of TF (P  .001) compared
with systemic cells. The number of platelets were 2 times
lower (P  .001) in SMB. Although few, the shed platelets
were activated and expressed 2 times more P-selectin com-
pared with that in circulating cells (P  .001). Moreover,
the amount of platelet microparticles was 7-fold higher in
the SMB than in systemic blood (P  .001). The release of
IL-6 and IL-8 was more than 40 and 36 times higher,
respectively, than in systemic blood (P  .001). However,
the level of IL-10 in SMB was not different from that in
systemic blood 3 hours after the operation (P  .2). The
level of sIL-2R was 2 times lower (P  .001) in SMB
compared with that in systemic blood. The formation of
thrombin was dramatic in the SMB, with F12 levels almost
200-fold the levels in systemic blood (P  .001). The level
of TAT was higher than 100 times the highest standard (ie,
6000 g/L), which was more than 280 times that in the
systemic blood (P  .001). The thrombin activity reflected
by sF was 13-fold higher (P  .001), and the fibrinolysis
was 6-fold greater than in circulating blood (P  .001), as
measured by PAP levels. The activation of the intrinsic
pathway was also increased in the shed blood, the level of
FXIa-AT was 130 times higher, and the level of FXIIa-AT
was more than 180 times higher (P  .001 for both)
Figure 5. PAP in plasma before, during, and after the operation in
patients. A, Uncoated group with ACT of 480 seconds (open
squares) and CHS-coated group with ACT of 480 seconds (filled
squares). *P  .02, **P .01, ***P  .006. B, CHS-coated group
with low heparin dose and ACT of 300 seconds (open triangles),
with high heparin dose and ACT of 600 seconds (filled triangles),
and with standard heparin dose and ACT of 480 seconds (filled
squares, dotted line). *P  .04, ACT of 300 seconds versus ACT of
600 seconds; **P .01; #P  .03, ACT of 300 seconds versus ACT
of 480 seconds; ##P  .01; ###P  .004; ¤P  .01, ACT of 600
seconds versus ACT of 480 seconds; ¤¤P  .004; ¤¤¤P  .001;
¤¤¤¤P < .001. Results are presented as median and 25th-75th
percentiles.
Figure 6. FXIIa-AT in plasma before, during, and after the opera-
tion in patients. A, Uncoated group with ACT of 480 seconds (open
squares) and CHS-coated group with ACT of 480 seconds (filled
squares). B, CHS-coated group with low heparin dose and ACT of
300 seconds (open triangles) and with high heparin dose and ACT
of 600 seconds (filled triangles). Results are presented as median
and 25th-75th percentiles.
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compared with that in systemic blood. The formation of
FXIIa-C1 INH in SMB was half the level in systemic blood
3 hours after the operation (P  .0014, Table 4).
Discussion
The foreign surfaces of extracorporeal equipment are pro-
coagulant and do activate the inflammation system. Heparin
coating improves biocompatibility of the surfaces, as re-
flected by reduced complement and granulocyte activation
and reduced production of proinflammatory cyto-
kines.11,25,26
Despite the fact that a number of experimental studies
have demonstrated inhibition of FXa and thrombin as a
result of immobilized heparin, many clinical studies using
heparin-coated bypass circuits have failed to demonstrate
reduced thrombin formation.18,27 To our knowledge, only
one study28 with heparin coating (Duraflo II surface)
showed reduced formation of thrombin. The seeming dis-
crepancy between the experimental and clinical results with
respect to activation of coagulation might reflect that a
number of factors in addition to the artificial surfaces, such
as pumping of blood, rheologic imperfections, surgical
trauma, and retransfusion of pericardial and SMB come into
play in the clinical setting.
The aim of the first part of this study was to investigate
the biocompatibility of a newly developed heparin surface,
the CHS. It should be emphasized that the CHS is a stable
heparin coating with no demonstrable release of heparin and
a high capacity to bind antithrombin. Judged by these char-
acteristics, the CHS is comparable with the Carmeda Bio-
active Surface but different from the Duraflo II, which is
based on an ionic complex with sustained release of heparin
and the cationic surfactant used in the complex with no
demonstrable capacity to bind antithrombin.
Markers of inflammation, coagulation, and fibrinolysis
were included in the analysis to obtain an overall view of
processes activated at blood contact with biomaterials. The
CHS significantly reduced the activation of coagulation,
fibrinolysis, platelets, and inflammation in comparison with
that on the uncoated surface in combination with a standard
dose of systemic heparin. These results indicate that the
CHS is more biocompatible than an uncoated surface, not
only in terms of inflammatory parameters but also in terms
of reduced thrombin generation.
The improved biocompatibility achieved by coating the
surface of the extracorporeal device with heparin has initi-
ated studies in which the dose of systemic heparin has been
reduced. However, these studies have presented conflicting
results. Some have shown a reduction of granulocyte acti-
vation11 and a lower incidence of homologous transfu-
sions,12 whereas others found it clinically safe but not in
favor to standard heparin levels in combination with avail-
able heparin surfaces.10,29 Yet others have concluded that a
reduction of systemic heparin should not be made because
of an increased formation of thrombin.30 An important
difference between various clinical studies is the use of
different surfaces and heparin doses at the same time.30,31
This design makes it hard to distinguish between the effects
of heparin coating and those induced by means of reduced
anticoagulation. Thus in the second part of the present
study, we investigated the effect of the CHS in combination
with a reduced or increased systemic heparin dose com-
pared with the standard systemic heparin dose used in part
1 in respect to inflammation, coagulation, and fibrinolysis.
In this study the reduced heparin dose was aimed at an
ACT at 300 seconds, although this was not quite accom-
plished. The results were 400 seconds before and 343 sec-
onds after CPB; however, these were significantly different
from that seen in the coated group with a standard heparin
level. The ratio between these 2 groups was constant during
CPB (Table 1). The decrease of systemic heparin in com-
bination with this new heparin-coated surface resulted in a
slightly beneficial effect on inflammation reflected by the
inflammatory marker MPO analyzed in this study. CD11b
expression on the surface of leukocytes and data on coag-
ulation and fibrinolysis, however, indicated elevated activa-
tion in the group with reduced heparin. These results might
be explained by a requirement of a certain amount of
TABLE 4. Markers of inflammation and coagulation in SMB
3 h after
operation in
patients
3 h after operation in
SMB
Leukocytes (109/L) 13.3 (11.1-15.5) 3.5 (2.6-4.7)†
CD11b granulocytes (MFI) 3.9 (3.2-5.0) 18.3 (15.7-21.8)†
CD11b monocytes (MFI) 4.4 (3.7-5.6) 21.7 (18.6-24.8)†
MPO (ng/mL) 70.3 (55.1-96.2) 1064 (909-1160)†
TF (MFI) 0.52 (0.48-0.58) 0.90 (0.82-1.11)†
Platelets (109/L) 133 (103-164) 47 (37-67)†
P-selectin (% of baseline) 112 (99-125) 248 (174-342)†
Platelet -particles (% of
baseline)
113 (85-133) 739 (488-970)†
IL-6 (pg/L) 160 (112-220) 6900 (5000-9600)†
IL-8 (pg/L) 28 (18-42) 1010 (770-1720)†
IL-10 (pg/L) 38 (17-42) 42 (21-44)
sIL-2R (pg/L) 760 (620-1010) 300 (260-380)†
F12 (nmol/L) 3.1 (2.3-4.7) 595 (472-932)†
TAT (g/L) 21.6 (14.0-31.3) 6000 (6000–6000)†
sF (mg/L) 22 (18-28) 285 (243-300)†
PAP (g/L) 1211 (921-1730) 7480 (5220-12,175)†
FXIa-AT 0.05 (0.03-0.07) 6.46 (4.49-10.0)†
FXIIa-AT 0.05 (0.02-0.08) 8.8 (5.52-16.0)†
FXIIa-CI INH 1.04 (0.63-1.74) 0.42 (0.23-0.71)*
No significant differences existed between the groups for the SMB.
Results are presented as one set and as median and 25th-75th percentiles.
MFI, Mean fluorescence intensity.
*Significantly different from values in patients 3 hours after the operation,
P  .0014.
†Significantly different from values in patients 3 hours after the operation,
P  .001.
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soluble heparin to downregulate the procoagulant activity
caused by the CPB and not accomplished by the surface per
se. Heparin induces secretion of TF pathway inhibitor from
endothelial cells in a dose-dependent manner, thus inhibit-
ing TF/FVIIa.32,33 Moreover, heparin can inhibit binding of
fibrinogen, factor X, iC3b, and intercellular adhesion mol-
ecule 1 to Cd11b/CD18.34 This might result in alteration of
leukocyte functions involved in the activation of coagula-
tion and inflammation.
The higher dose of systemic heparin (ACT of 600 sec-
onds) in combination with the heparin surface was designed
to clarify whether modulation of inflammation and coagu-
lation by means of heparin could be further improved.
However, the results from this group demonstrated the
opposite, with increased activation of coagulation. Heparin
is known to exert a variety of effects on cells in the vessel
walls and circulation. Heparin potentiates platelet aggrega-
tion, recently shown to be caused by decreased nitric oxide
production, an important endogenous inhibitor of platelet-
mediated thrombosis.35 This observation might in part ex-
plain the prothrombotic effects of the high dose of heparin.
Contact activation was reflected distinctly differently by
the appearance of FXIIa-AT and FXIa-AT complexes, re-
spectively. Whereas FXIa was reduced in group 2 compared
with that seen in groups 3 and 4, there were no differences
among the groups with respect to FXIIa. Quite interestingly,
the generation of FXIIa started earlier, after sternotomy,
with no further increase during CPB in groups 1 and 2. It
has been reported that the capacity of the natural endothe-
lium to inhibit FXIIa is impaired after systemic administra-
tion of heparin,36 which might explain the early appearance
of FXIIa, irrespective of the type of extracorporeal circuit,
after heparinization of the patient. Because the generation of
FXIa is greatly influenced by a thrombin feedback loop,37 it
seems plausible that the time course and relative concentra-
tions of FXIa would coincide with those of thrombin for-
mation. Reduced contact activation in connection with the
use of Duraflo II has previously been reported.7 However,
this conclusion was based on reduced formation of kalle-
krein-CI INH complexes, with no direct measurements of
FXIIA or FXIa or any signs of decreased thrombin forma-
tion.
TF is not normally expressed in the circulation. Mono-
cytes in samples taken from the pericardial cavity have been
shown to express approximately 2-fold increased TF on the
cell surface3 in a study performed with an uncoated extra-
corporeal device. Our results are confirming, with no dif-
ferences between the groups. The use of cardiotomysuction
in this study with recirculation of the blood might contribute
to the increased platelet activity and thrombin generation
seen directly after the operation in this study. However, all
groups in the study have been treated according to the same
routine, and we therefore believe that comparisons between
the groups can be made.
Activation of coagulation and inflammation during CPB
is a complex interplay involving both the intrinsic and, to a
larger extent, the TF pathways. In experimental studies with
simulated extracorporeal circulation, thrombin generation
occurs before TF expression on monocytes, the only blood
cell able to express TF, indicating a role of the intrinsic
pathway.38 In vivo, the surgical trauma with exposure of TF
and involvement of inflammation makes the picture more
complex.
Autotransfusion of shed blood after cardiac surgery is an
often-used method to reduce the exposure of patients to
homologous blood,14,15 however debated.17,22,39 Differences
of threshold levels for transfusion between countries and
clinics further complicates the possibility to evaluate and
compare these studies.40 In our study, in which no auto-
transfusion was performed, 30% of the patients needed
homologous blood and received 2.2 units per patient, or a
total of 0.67 units per patient. Furthermore, the quality of
shed blood has been questioned,39,41 with indications of
defective hemostasis19,22,42 and reports of systemic blood
activation21 and more febrile patients39 after autotransfusion
of this blood.
We found, in agreement with previous studies, that the
SMB after CPB was characterized by activated cells, ex-
traordinary activated coagulation, and inflammatory pro-
cesses. The shed blood contained few cells but with a high
expression of surface markers, indicating elevated activa-
tion. The low number of cells might be caused by adhesion,
lysing, or dilution by means of exsudation.
In this study autotransfusion was not performed, and the
duration of increased inflammatory and coagulant activity
appeared to be shorter compared with that seen in previous
studies in which shed blood was retransfused.20,27,41,42 The
high postsurgical levels of thrombin formation may be a
consequence of the autotransfusion. Thrombin has been
shown to induce several cell responses involved in inflam-
mation, including, among others, cytokine release in mono-
cytes and endothelial cells.43 In contrast, the levels of IL-10,
an anti-inflammatory cytokine and a potent inhibitor of
monocyte activation and with anticoagulant effect,44 did not
differ between systemic blood and shed blood. Conse-
quently, the imbalance between the cytokines in shed blood
may reflect ongoing activity with subsequent effects on the
coagulation and inflammatory systems.
During part 1 of the present study, we could conclude
that the newly developed heparin surface is more biocom-
patible than an uncoated surface. The differences seen be-
tween parts 1 and 2 of the study are merely reflecting the
importance of the systemic heparin level than the effect of
the surface. The low dose of systemic heparin may not be
sufficient to maintain the antithrombotic activity at the same
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level as a standard heparin dose during this kind of opera-
tion. The high dose, on the other hand, resulted in a direct
cell-activating situation rather than a further anti-inflamma-
tory and anticoagulatory effect.
We thank Birgitta Fahlstro¨m for skillful technical assistance.
We are also much obliged to the medical and nursing staff at all
wards, especially Eric Halde´n and Anita Bertilsson, and above all
to the patients for their participation.
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